Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Apyx Medical (APYX) over the last 15 years, with Q3 2025 value amounting to $164000.0.

  • Apyx Medical's Depreciation & Amortization (CF) rose 1388.89% to $164000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $576000.0, marking a year-over-year decrease of 541.87%. This contributed to the annual value of $599000.0 for FY2024, which is 1343.93% down from last year.
  • As of Q3 2025, Apyx Medical's Depreciation & Amortization (CF) stood at $164000.0, which was up 1388.89% from $132000.0 recorded in Q2 2025.
  • Over the past 5 years, Apyx Medical's Depreciation & Amortization (CF) peaked at $247000.0 during Q2 2022, and registered a low of $132000.0 during Q2 2025.
  • For the 5-year period, Apyx Medical's Depreciation & Amortization (CF) averaged around $185157.9, with its median value being $186000.0 (2023).
  • Per our database at Business Quant, Apyx Medical's Depreciation & Amortization (CF) skyrocketed by 1596.24% in 2022 and then plummeted by 3886.64% in 2023.
  • Quarter analysis of 5 years shows Apyx Medical's Depreciation & Amortization (CF) stood at $229000.0 in 2021, then fell by 11.79% to $202000.0 in 2022, then fell by 24.75% to $152000.0 in 2023, then fell by 6.58% to $142000.0 in 2024, then rose by 15.49% to $164000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $164000.0 for Q3 2025, versus $132000.0 for Q2 2025 and $138000.0 for Q1 2025.